Company intelligence / Profile preview
GenSight Biologics
Paris, Francegensight-biologics.com ↗
- Ownership
- Public · SIGHT
- Employees
- ~16
- Development stage
- Phase 3
01
Overview
GenSight Biologics’ lead candidate LUMEVOQ® has completed three Phase III trials for LHON caused by ND4 mutations, showing significant and sustained visual function improvement compared to natural history. The company is planning an additional Phase III trial after regulatory feedback. GS030, their optogenetic gene therapy for retinitis pigmentosa, is showing efficacy signals in ongoing Phase I/II studies. CMC challenges have been addressed for LUMEVOQ®, with new regulatory submissions planned.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyRecombinant proteinOptogenetics-based therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Academic license agreements with Sorbonne Université, CNRS, Inserm & SATT LutechInserm Transfert S.A.GenethonHarvard UniversityMassachusetts Institute of TechnologyNovartis Pharma AGAdverum Biotechnologies
Beyond the preview
Go deeper on GenSight Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenSight Biologics.